alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.2



CERTIFICATION UNDER

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of Glacier Water Services, Inc., (the Company) on Form 10-Q for the period ended September 28, 2003 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, W. David
Walters, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to and for purposes of 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates indicated and results of operations of the
Company for the periods indicated.
| | --- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|/s/ W. David Walters                             
|-------------------------------------------------
|W. David Walters                                 
|Senior Vice President and Chief Financial Officer
|November 7, 2003
Steven R. PHELPS, Appellant, v. STATE of Florida, Appellee.

Case No. 2D17-4210

District Court of Appeal of Florida, Second District.

Opinion filed March 21, 2018

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
##### 



EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Brion Umidi, the Chief Financial Officer of ReGen Biologics,
Inc. (the Company), has executed this certification in connection with the
filing with the Securities and Exchange Commission of the Companys Quarterly
Report on Form 10-Q/A-1 for the quarterly period ending September 30, 2003 (the
Report). The undersigned hereby certifies that:

(1)  the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)  the information contained in the Report fairly presents, in all material respects, the financial condition and results of
operations of the Company.

|                    |  |                               
|------------------- |  | ------------------------------
|Date: June 16, 2004 |  | /s/ Brion Umidi               
|                    |  |                               
|                    |  | Name: Brion Umidi             
|                    |  | Title: Chief Financial Officer
[Federal Register Volume 87, Number 28 (Thursday, February 10, 2022)]
[Notices]
[Page 7847]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-02788]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of General Medical Sciences; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis Panel; NIGMS Review of Centers of 
Biomedical Research Excellence (COBRE) Phase 2 Applications.
    Date: March 17-18, 2022.
    Time: 10:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Natcher Building, 45 
Center Drive, Bethesda, MD 20892 (Video Meeting).
    Contact Person: Nina Sidorova, Ph.D., Scientific Review Officer, 
Office of Scientific Review, National Institute of General Medical 
Sciences, National Institutes of Health, 45 Center Drive, Room 
3An.22, Bethesda, MD 20892-6200, 301-594-3663, 
<a href="/cdn-cgi/l/email-protection#304359545f425f4651705e59575d431e5e59581e575f46"><span class="__cf_email__" data-cfemail="2e5d474a415c41584f6e404749435d0040474600494158">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, 
Pharmacology, Physiology, and Biological Chemistry Research; 93.859, 
Biomedical Research and Research Training, National Institutes of 
Health, HHS)

     Dated: February 4, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-02788 Filed 2-9-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Darren T. VALMYR, Appellant, v. STATE of Florida, Appellee.

No. 4D17-90

District Court of Appeal of Florida, Fourth District.

[March 29, 2018]

Carey Haughwout, Public Defender, and Patrick B. Burke, Assistant Public Defender, West Palm Beach, for appellant.

Pamela Jo Bondi, Attorney General, Tallahassee, and Mitchell A. Egber, Assistant Attorney General, West Palm Beach, for appellee.

Per Curiam.

*Affirmed.*

Ciklin, Conner, JJ., and Roberts, Kathleen H., Associate Judge, concur.
exv10w24






Exhibit 10.24




SUMMARY OF BOARD COMPENSATION



Non-employee directors of Pacific Sunwear of California, Inc. (the “Company”) receive compensation
for their services to the Board of Directors and related committees as follows:




	 	 	 	 	 
	Amount	 	Description
	$	50,000	 	 	Lead director annual retainer, disbursed in five equal payments for each
regularly scheduled Board meeting.

	 	 	 	 	 

	 	30,000	 	 	Annual retainer for all other non-employee directors, disbursed in five equal
payments for each regularly scheduled Board meeting.

	 	 	 	 	 

	 	10,000	 	 	Audit committee chairman annual retainer, disbursed in same manner as Board
member annual retainer (excludes lead director).

	 	 	 	 	 

	 	5,000	 	 	Non-audit committee chairman annual retainer, disbursed in same manner as Board
member annual retainer (excludes lead director).

	 	 	 	 	 

	 	3,000	 	 	Attendance fee for each in-person Board meeting.

	 	 	 	 	 

	 	1,250	 	 	Attendance fee for each telephonic Board meeting or committee meeting of any kind.







     All directors are reimbursed for expenses incurred in attending meetings of the Board of
Directors.1 Each non-employee director of the Company currently receives, and will
continue to receive, an annual award grant of 9,000 stock appreciation rights, which have a base
price equal to the closing market price of the Company’s common stock on the date of the grant and
are payable in shares of common stock. Sally Frame Kasaks, who is the Chief Executive Officer of
the Company, is not paid any fees or additional remuneration for her services as a member of the
Board of Directors.





 




			
	1	 	To the extent any expense reimbursements provided for
in this Summary of Board Compensation are taxable to a director and provide for
a deferral of compensation within the meaning of Section 409A of the Internal
Revenue Code, the director shall complete all steps required for reimbursement
so as to facilitate payment, and any such reimbursements shall be paid to the
Director on or before December 31 of the calendar year following the calendar
year in which the expense was incurred. Such reimbursements shall not be
subject to liquidation or exchange for other benefits, and the expenses
eligible for reimbursement in one calendar year shall not affect the expenses
eligible for reimbursement in any other calendar year.
Exhibit 31.3

CERTIFICATION

I, Josef
H. von Rickenbach, certify that:



| | 1. | I have reviewed this Amendment No. 1 on Form 10-K/A of PAREXEL International Corporation; and
| | -- | ---------------------------------------------------------------------------------------------



| | 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
| | -- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|                        |  |  |  |                                                                                
|----------------------- |  |  |  | -------------------------------------------------------------------------------
|Date: September 9, 2010 |  |  |  |                                                                                
|                        |  | 
|                        |  |  |  | /s/ Josef H. von Rickenbach                                                    
|                        |  |  |  | Josef H. von Rickenbach                                                        
|                        |  |  |  | Chairman of the Board and Chief Executive Officer
(principal executive officer)
<PAGE>

                                                                    Exhibit 99.1


                           CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Umbrella Bancorp, Inc. (the
"Company") on Form 10-Q for the period ending June 30 2002 as filed with the
Securities Exchange Commission on the date hereof (the "Report"), I, John G.
Yedinak, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.
1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.


/s/ John G. Yedinak


John G. Yedinak
Chief Executive Officer
August 26, 2002
#### Lloyd H. MAUPIN, Appellant, v. UNITED STATES of America, Appellee.

No. 5324.

United States Court of Appeals Tenth Circuit.

April 16, 1956.

Writ of Certiorari Denied June 4, 1956.

See 76 S.Ct. 1036.

Lloyd H. Maupin, pro se.

. Robert Swanson, Asst. U. S. Atty., Denver, Colo. (Donald E. Kelley, U. S. Atty., Denver, Colo., on the brief), for appellee.

*839Before BRATTON, Chief Judge, and HUXMAN and PICKETT, Circuit Judges.

PER CURIAM.

Lloyd H. Maupin was indicted and convicted, with two others, on a charge of robbing, and conspiring to rob, the Metropolitan State Bank at Derby, Colorado, a bank insured by the Federal Deposit Insurance Corporation. Maupin’s conviction was affirmed by this court. Maupin v. United States, 10 Cir., 225 F.2d 680. This proceeding was instituted under the provisions of 28 U.S. C.A. § 2255, to vacate the judgment and sentence. The District Court denied relief. One of the grounds set forth in the motion is that no federal offense had been committed because the Derby bank was not in fact insured by the Federal Deposit Insurance Corporation. The basis of this contention is that the insurance certificate was not effective because the Federal Deposit Insurance Corporation had not qualified to do business in the State of Colorado as required by the Colorado statutes, therefore could not legally issue a certificate of insurance. We disposed of this matter in a companion case brought by a co-defendant, where it was said:

> “The Federal Statute creating the Federal Deposit Insurance Corporation, 12 U.S.C.A. § 264, authorizes that corporation to issue insurance certificates to qualified state banks. The Colorado Statutes specifically authorize state banks to contract for insurance with the Federal Deposit Insurance Corporation. Colorado Revised Statutes 1953, Chapter 14, Art. 9, § 6.” Atterson v. United States, 10 Cir., 232 F.2d 837.

It is also contended in support of the motion that the sentence on the first count of the information was void because at the trial of the case the evidence showed that the petitioner was an aider and abettor to the crime and he was charged as a principal. Under the statute, an aider and abettor is a principal and so charged. 18 U.S.C.A. § 2; Nye & Nissen v. United States, 336 U.S. 613, 69 S.Ct. 766, 93 L.Ed. 919.

Furthermore, these alleged errors do not go to the validity of the judgment but were of such nature that they could be reviewed only on appeal. The purpose of § 2255 was to provide a method of attack upon a judgment and sentence which might theretofore have been made by habeas corpus. It does not give a prisoner the right to obtain a review of errors of law and fact which must be raised by timely appeal. Barnes v. Hunter, 10 Cir., 188 F.2d 86; Hurst v. United States, 10 Cir., 177 F.2d 894. Other errors alleged to have been committed by the court in the trial of the criminal case were all such as could be reviewed only on appeal.

Affirmed.
#### VIRNETX INC., Appellant v. APPLE INC., Appellee

2016-1211

2016-1213

2016-1279

2016-1281

United States Court of Appeals, Federal Circuit.

Decided: December 9, 2016

Joseph Palys, Paul Hastings LLP, Washington, DC, argued for appellant. Also represented by Naveen Modi, Danielle Ruth Acker Susanj, Igor Victor Ti-mofeyev, Daniel Zeilberger.

John C. O’Quinn, Kirkland <& Ellis LLP, Washington, DC, argued for appellee. Also represented by Nathan S. Mammen; Jeffrey Paul Kushan, Sidley Austin LLP, Washington, DC.

Before O’Malley, Mayer, and Wallach, Circuit Judges.

O’Malley, Circuit Judge.

This appeal concerns the validity of Vir-netX Inc.’s (“VirnetX”) U.S. Patent Nos. 7,188,180 (“the 180 patent”) and 7,987,274 (“the ’274 patent”), disclosing technology for establishing secure communication over networks. Apple Inc. (“Apple”) challenged claims of the ’274 patent in two *inter partes*review proceedings, which were consolidated with IPR2014-00403 (“the 403 proceeding”) and IPR2014-00404 (“the 404 proceeding”) initiated by Microsoft Corporation on similar grounds. Apple *787relied principally on U.S. Patent No. 6,557,087 to Provino (“Provino”) and Tak-ahiro Kiuchi *&*Shigekoto Kaihara, *C-HTTP—The Development of a Secure, Closed HTTP-based Network on the Internet*(Feb. 1996) (“Kiuchi”), respectively, for each proceeding. Apple also challenged claims of the ’180 patent in two *inter partes*review proceedings, IPR2014-00481 (“the 481 proceeding”) and IPR2014-00482 (“the 482 proceeding”), again relying principally on Provino and Kiuchi, respectively. VirnetX now appeals to this court.

After full review of the record and careful consideration, we find no error in the Patent Trial and Appeal Board’s (“the Board”) claim constructions or findings in the 403 and 481 proceedings. For the reasons given by the Board therein, we find the challenged claims unpatentable over Provino and the additional prior art cited. We do not, therefore, need to reach the merits of the Board’s decisions in the 404 and 482 proceedings.

AFFIRMED
Document

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.



SECOND AMENDMENT to OPTION FOR A LICENSE AGREEMENT




This Second Amendment entered into on the date of last signature to this First Amendment by and between MacroGenics, Inc. a Delaware corporation having a principal office located at 9704 Medical Center Drive, Rockville, MD  20850 (“MacroGenics”) ′′), and Les Laboratoires Servier, a company organized and existing under the laws of France, having a principal office located at 50 rue Carnot 92284 Suresnes (“LLS”) and Institut de Recherches Servier, a company organized and existing under the laws of France, having a principal office located at 3 rue de la République - 92150 Suresnes - France (“IdRS”) and LLS and IdRS hereinafter collectively referred to as “Servier”).  MacroGenics and Servier are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
WHEREAS, Servier and MacroGenics executed an Option for a License Agreement on September 19, 2012, as amended on 14 June 2017 (the “Agreement”);
WHEREAS, the Parties wish to further amend the Agreement as set forth below;
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree to the following terms and conditions:
1.   All capitalized terms used in this Second Amendment, but not otherwise defined herein, shall have the meanings ascribed to such terms in the Agreement.
2.   Article 1.64(b) shall be deleted in its entirety and replaced with the following:
“with respect to each of the A33 Program [***].”
3.   This Second Amendment and the Agreement constitute the entire agreement of the parties and supersedes any and all prior agreements, written or oral, between Servier and MacroGenics relating to the subject matter of this First Amendment and the Agreement and neither may be amended unless agreed to in writing by both parties.
[Signature page follows]















THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.



IN WITNESS WHEREOF, the parties, intending to be legally bound, have caused this First Amendment to be executed by their respective duly authorized representative.




															
	MacroGenics, Inc.
			Les Laboratoires
	
					
	Name: 	[***] 		Name: 	[***] 
		[***] 			
					
	Title: 	[***] 		Title: 	[***] 
					
	Date: 	[***] 		Date: 	[***] 
					
					
				Institut de Recherches Servier  	
					
				Name: 	[***] 
					
					
				Title: 	[***] 
					
				Date: 	[***]
### Michigan Supreme Court Lansing, Michigan

Marilyn Kelly, Chief Justice

Michael F. Cavanag h
Elizabeth A. Weave r

Maura D. Corriga n Robert P. Young, Jr. Stephen J. Markma n Diane M. Hathaway,
J ustices

I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

_______________________________________ __ Clerk April 28, 2009

s0420 

# Order

April 28, 2009

137746

PEOPLE OF THE STATE OF MICHIGAN, Plaintiff-Appellee,

v SC: 137746 COA: 286699 Kent CC: 01-004370-FC JENDRI MALDONADO-ZAPON, Defendant-Appellant.

________________ _______________ __________/

On order of the Court, the application for leave to appeal the October 10, 2008 order of the Court of Appeals is considered , and it is DENIED, because the defendant has
failed to meet the burden of establishi ng entitlement to relief under MCR 6.508(D).
EX-4.C






Exhibit 4(c)




FIRST AMENDMENT TO




MERCANTILE BANK CORPORATION




EMPLOYEE STOCK PURCHASE PLAN OF 2002




     THIS AMENDMENT to the Mercantile Bank Corporation Employee Stock Purchase Plan of 2002 (the
“Plan”) is adopted effective as of February 28, 2009.



     WHEREAS, the Board of Directors of Mercantile Bank Corporation (the “Company”) adopted
the Plan effective as of October 1, 2002;



     WHEREAS, Section 10.2 of the Plan authorizes the Committee or the Board of Directors of the
Company to adopt amendments to the Plan;



     WHEREAS, the Company wishes to increase the number of shares available for purchase under the
Plan from 25,000 to 55,000;



     NOW, THEREFORE, this Amendment is adopted, effective as of February 28, 2009:



     1. Section 4.1 of the Plan is amended in its entirety as follows:



     “4.1 Number of Shares of Common Stock. There shall be reserved for issuance to and purchase
by Participants under the Plan an aggregate of 55,000 shares of Common Stock, subject to adjustment
as provided in Section 4.2. Shares of Common Stock available under the Plan shall be authorized
and unissued shares or shares purchased by the Company.”



     2. Capitalized terms used in this Amendment and not defined have the meanings given to them in
the Plan. Except as hereby amended, the Plan shall remain in full force and effect.



     IN WITNESS WHEREOF, this Amendment is executed by an authorized officer of the Company.



	 	 	 	 	 
	 	 	MERCANTILE BANK CORPORATION
	 
	 	 	 	 
	 

	 	By:
	 	/s/ Michael H. Price
	 
	 	 	 	 
	 

	 	Its:
	 	Chairman and CEO






Approved by the Board of Directors on February 26, 2009

Effective: February 28, 2009
EX PARTE Tommy STURDIVANT

CR-16-0023

Court of Criminal Appeals of Alabama.

February 1, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Mand. pet. dismissed.
I 

117TH CONGRESS 

1ST SESSION H. R. 1320 

To amend title 5, United States Code, to establish Juneteenth Independence 

Day as a Federal holiday, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 25, 2021 

Ms. JACKSON LEE (for herself, Mrs. BUSTOS, Mr. CONNOLLY, Ms. MENG, Ms. 

CLARKE of New York, Mr. WELCH, Mr. COOPER, Mr. BISHOP of Georgia, 

Mr. KILDEE, Mr. HASTINGS, Ms. MOORE of Wisconsin, Ms. NORTON, 

Mr. BEYER, Mr. LARSEN of Washington, Ms. LEE of California, Ms. 

WILLIAMS of Georgia, Mr. TRONE, Mr. SCHNEIDER, Mrs. BEATTY, Mr. 

MCNERNEY, Ms. DEGETTE, Ms. CLARK of Massachusetts, Ms. SEWELL, 

Mr. NEGUSE, Ms. SPEIER, Ms. DELBENE, Mr. JEFFRIES, Mr. MEEKS, 

Ms. WILSON of Florida, Ms. MCCOLLUM, Mr. CA ́RDENAS, Mr. COHEN, 

Mr. STANTON, Mr. HIGGINS of New York, Mr. SUOZZI, Mr. MFUME, Ms. 

SCHAKOWSKY, Mr. DAVID SCOTT of Georgia, Ms. TITUS, Ms. ROYBALALLARD, Ms. BONAMICI, Mr. KILMER, Mr. RASKIN, Ms. LOIS FRANKEL

of Florida, Mr. MCGOVERN, Ms. ADAMS, Mr. JONES, Mr. RUPPERSBERGER, Mr. BLUMENAUER, Mrs. LURIA, Mr. LAWSON of Florida, Mr. 

MORELLE, Mr. PALLONE, Mrs. FLETCHER, Ms. JAYAPAL, Mr. YARMUTH, 

Mr. PAYNE, Mr. THOMPSON of Mississippi, Mr. COSTA, Mr. HORSFORD, 

Ms. CASTOR of Florida, Mrs. LAWRENCE, Ms. VELA ́ZQUEZ, Ms. PINGREE, Mrs. DINGELL, Mr. EVANS, Mr. RUSH, Mr. MCEACHIN, Ms. GARCIA of Texas, Ms. TLAIB, Mr. SARBANES, Ms. WILD, Mrs. DEMINGS, 

Mrs. HAYES, Mr. PRICE of North Carolina, Mr. SEAN PATRICK MALONEY of New York, Mr. LOWENTHAL, Mr. PHILLIPS, Mr. CUELLAR, Mr. 

WEBER of Texas, Ms. DEAN, Mr. CASTEN, Ms. ESHOO, Mr. 

DESAULNIER, Mr. POCAN, Mr. VEASEY, Mr. CARSON, Miss RICE of New 

York, Mr. JOHNSON of Georgia, Mr. SIRES, and Mr. DANNY K. DAVIS

of Illinois) introduced the following bill; which was referred to the Committee on Oversight and Reform 

A BILL 

To amend title 5, United States Code, to establish 


kjohnson on DSK79L0C42PROD with BILLS
2 

•HR 1320 IH

Juneteenth Independence Day as a Federal holiday, and 

for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Juneteenth National 

5 Independence Day Act’’. 

6 SEC. 2. JUNETEENTH INDEPENDENCE DAY. 

7 Section 6103(a) of title 5, United States Code, is 

8 amended by inserting after the item relating to Memorial 

9 Day the following: 

10 ‘‘Juneteenth Independence Day.’’. 

Æ 


kjohnson on DSK79L0C42PROD with BILLS